Skip to main content
. Author manuscript; available in PMC: 2020 Feb 16.
Published in final edited form as: Bone Joint J. 2019 Jul;101-B(7 SUPPLE C):108–114. doi: 10.1302/0301-620X.101B7.BJJ-2018-1473.R1

Fig. 2.

Fig. 2

a) and b) Anti-vascular endothelial growth factor receptor (VEGFR) treatment decreased the number of CD31hiEMCNhi cells in peri-implant bone detected by flow cytometry (the middle line indicates the mean, and the other two lines represent the standard deviation). c) Anti-VEGFR treatment decreased the CD31 and endomucin (EMCN) double-positive cells (yellow) detected by immunofluorescence. d) Anti-VEGFR inhibited bone morphogenetic protein 2 (BMP2) and insulin-like growth factor 2 (IGF2) expressions in these sorted CD31hiEMCNhi cells. e) Gene ontology (GO) enrichment analysis of differentially expressed genes between control mice and anti-VEGFR treated mice. Each bar is coloured and labelled according to p-value of enrichment analysis. *p < 0.05. Scale bar: 250 μm. DAPI, diamidino-2-phenylindole; FGF2, fibroblast growth factor 2.